Nicotinamide Riboside May Reduce Airway Inflammation in COPD

A new study explores how boosting NAD+ levels could help manage chronic lung disease

Topline:

A randomized, placebo-controlled trial suggests that nicotinamide riboside (NR), an NAD+ precursor, may significantly reduce airway inflammation in patients with COPD, potentially improving disease management and reducing exacerbation risks.

Study Details

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that aff…